Boston Scientific Corporation ($BSX) Stock Forecast: Up 5.2% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) Market: Boston Scientific (BSX) had a bullish movement today, outperforming the broader market.

Why is Boston Scientific Corporation going up?

BSX stock is up 5.2% on Jan 8, 2025 18:37

• Boston Scientific's recent acquisition of Bolt Medical for over $440 million has expanded its cardiovascular treatment portfolio, showcasing growth and innovation in its offerings.
• Achieving a 52-week high reflects strong investor confidence and indicates potential for further gains going forward.
• Despite market fluctuations, Boston Scientific's resilience and positive performance highlight its strength and attractiveness to investors.
• The ongoing sales growth in endoscopy operations beyond the U.S. demonstrates Boston Scientific's adeptness in navigating competition and sustaining a competitive advantage in the market.

BSX Price Chart

BSX Technical Analysis

BSX News

Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal - Boston Scientific ( NYSE:BSX )

On Wednesday, Boston Scientific Corporation BSX agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy ( IVL ) advanced laser-based platform for coronary and peripheral artery disease.

https://www.benzinga.com/general/health-care/25/01/42881585/boston-scientific-expands-cardiovascular-treatment-portfolio-with-440-million-bolt-medical-de

Boston Scientific Corporation ( BSX ) Hits Fresh High: Is There Still Room to Run?

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

https://www.zacks.com/stock/news/2393623/boston-scientific-corporation-bsx-hits-fresh-high-is-there-still-room-to-run

Boston Scientific ( BSX ) Gains As Market Dips: What You Should Know

Boston Scientific (BSX) reachead $91.99 at the closing of the latest trading day, reflecting a +0.77% change compared to its last close.

https://www.zacks.com/stock/news/2393330/boston-scientific-bsx-gains-as-market-dips-what-you-should-know

Endoscopy Sales Growth to Support BSX Stock Amid Fierce Competition

Boston Scientific successfully continues its expansion of operations across different geographies outside the United States.

https://www.zacks.com/stock/news/2393120/endoscopy-sales-growth-to-support-bsx-stock-amid-fierce-competition

Boston Scientific ( BSX ) Outperforms Broader Market: What You Need to Know

In the most recent trading session, Boston Scientific (BSX) closed at $91.29, indicating a +0.66% shift from the previous trading day.

https://www.zacks.com/stock/news/2392544/boston-scientific-bsx-outperforms-broader-market-what-you-need-to-know

Trending Today

Worldcoin ($WLD) Crypto Forecast: Up 6.8% Today

XRP ($XRP) Crypto Forecast: Up 9.9% Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 6.0% Today

IOST ($IOST) Crypto Forecast: Up 5.8% Today

Movement ($MOVE) Crypto Forecast: Up 5.1% Today

Polkadot ($DOT) Crypto Forecast: Up 6.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 10.1% Today

Binance Coin ($BNB) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 6.2% Today

Boston Scientific Corporation Price History

23.09.2024 - BSX Stock was down 5.0%

• Despite exceeding Q3 earnings and revenue estimates, BSX faced a significant bearish movement in the market today.
• Investor sentiment in the options market may have contributed to the downward pressure on BSX stock.
• A downgrade by a top Wall Street analyst could have influenced the bearish movement.
• The recent FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, which was anticipated to drive up BSX shares, did not lead to a notable impact on the market today.

24.09.2024 - BSX Stock was up 2.3%

• Boston Scientific Corporation paused enrollment in the Farapulse study for drug-naive patients with irregular heart rhythm, a move that could enhance product safety and efficacy, potentially boosting investor confidence.
• Despite a slight premarket stock decline linked to a decrease in operating margin, BSX posted promising Q3 earnings surpassing revenue and EPS expectations, resulting in an improved annual forecast. This financial success likely contributed to the bullish market activity.
• Investors' optimistic outlook on Boston Scientific, demonstrated through options trading patterns, signifies a high level of confidence in the company's future growth prospects, further fueling the stock's uptrend.
• The strong performance in legacy businesses and robust demand for heart devices shown in the Q3 earnings report may have also been key factors in driving BSX towards a bullish market movement today.

08.00.2025 - BSX Stock was up 5.2%

• Boston Scientific's recent acquisition of Bolt Medical for over $440 million has expanded its cardiovascular treatment portfolio, showcasing growth and innovation in its offerings.
• Achieving a 52-week high reflects strong investor confidence and indicates potential for further gains going forward.
• Despite market fluctuations, Boston Scientific's resilience and positive performance highlight its strength and attractiveness to investors.
• The ongoing sales growth in endoscopy operations beyond the U.S. demonstrates Boston Scientific's adeptness in navigating competition and sustaining a competitive advantage in the market.

08.00.2025 - BSX Stock was up 6.2%

• BSX stock closed at $91.29 today, marking a +0.66% increase from the previous trading day.
• The positive movement in BSX stock is linked to the company's successful expansion internationally, especially in the field of endoscopy, which is anticipated to boost sales.
• Despite a downturn in the overall market, Boston Scientific showed strength, indicating resilience and potential growth in the near future.
• Market sentiment positions BSX as one of the standout performers in non-tech sectors for 2024, showing investor confidence in its future.

09.11.2024 - BSX Stock was down 1.5%

• The bearish movement in BSX could be attributed to insider selling activity by Emily Woodworth, a senior executive at the company, potentially raising concerns among investors about the company's future prospects.
• The overall market sentiment might have also played a role in the stock's decline, as investors may have been cautious due to uncertainties in the broader market.
• Despite the dip, BSX's long-term growth prospects and innovative product pipeline could still make it an attractive investment opportunity for those looking to capitalize on the healthcare sector's potential.

27.10.2023 - BSX Stock was down 1.0%

• The bearish movement in BSX's stock today could be attributed to several factors:
• 1. Profit-taking: After a significant increase in the stock price over the past month and year, some investors may have decided to sell their shares and take profits, leading to a downward pressure on the stock.
• 2. Market sentiment: The overall market sentiment towards healthcare stocks may have turned negative, causing investors to sell off their positions in BSX and other healthcare companies.
• 3. Lack of positive news: While there have been recent acquisitions and advancements mentioned in the news articles, there may not have been any specific positive news or developments directly impacting BSX today, leading to a lack of catalysts to drive the stock price higher.
• 4. Technical factors: The stock's price movement could also be influenced by technical factors, such as resistance levels or trading patterns, which may have triggered selling pressure.
• Overall, the bearish movement in BSX's stock today could be a result of profit-taking, negative market sentiment, lack of positive news, and technical factors.

24.03.2024 - BSX Stock was up 5.8%

• Boston Scientific (BSX) had a strong bullish movement today.
• This upward trend is linked to the company surpassing expectations in its first-quarter earnings report and providing optimistic guidance.
• First-quarter revenues of $3.86 billion exceeded the consensus estimate of $3.69 billion, demonstrating robust performance in core business areas.
• Shareholders responded positively to the positive earnings report, propelling the stock to achieve a 52-week high as they view Boston Scientific as a promising investment opportunity within the medical products industry.

24.03.2024 - BSX Stock was up 8.4%

• Boston Scientific (BSX) reported Q1 earnings and revenues that surpassed estimates, indicating strong financial performance and market confidence in the company's growth prospects.
• The positive earnings report and exceeding sales expectations propelled Boston Scientific's stock into buy zones, attracting investors and driving the bullish movement.
• The overall bullish market sentiment, with US broader indices up over 1% and stocks rising for the second consecutive day, also contributed to the upward momentum of BSX.
• Additionally, Boston Scientific received an IBD stock rating upgrade, further boosting investor confidence and interest in the company's stock.

11.02.2024 - BSX Stock was down 1.5%

• The stock of Boston Scientific (BSX) experienced a bearish movement despite being upgraded to a "buy" rating.
• The allegations against a former employee involved in a disturbing case of child abuse may have negatively impacted investor sentiment and contributed to the stock's decline.
• Despite the negative news surrounding the company, Boston Scientific has shown strong long-term performance, with a $1000 investment 10 years ago yielding significant returns.
• The market may have reacted to the news about Align Technology's improving technical performance, leading investors to shift focus away from Boston Scientific temporarily.

07.05.2024 - BSX Stock was up 1.9%

• Boston Scientific's stock showed a strong upward trend today, closing at $76.12, reflecting a +0.3% increase compared to the previous day.
• Concerns may have arisen initially due to an EVP selling over $500k in company stock; however, the overall positive market outlook and the company's solid fundamentals likely mitigated any apprehensions among investors.
• The company's consistent market outperformance over the last 15 years, with an average annual return of 14.9%, is a contributing factor to the high level of confidence and interest from investors.
• With an improved SmartSelect Composite Rating of 96, signaling that it is surpassing 96% of all stocks based on key criteria, Boston Scientific continues to receive favorable market sentiment.

01.06.2024 - BSX Stock was down 0.5%

• A conference call was announced by Boston Scientific to discuss its second-quarter 2024 results, which could have heightened investor anticipation and led to profit-taking.
• The positive news of securing a CE Mark for the DBS image-guided programming software might not have been sufficient to offset broader market trends or specific company performance concerns.
• The overall bearish movement in the market, particularly in the healthcare sector, could have influenced BSX's downward trajectory despite the positive developments within the company.
• The sector rotation away from tech and towards healthcare might have created uncertainty and volatility for BSX and contributed to the bearish market movement.

18.06.2024 - BSX Stock was down 1.2%

• Analysts predict that Boston Scientific Corporation (BSX) will announce an increase in revenue and adjusted earnings for the second quarter. Despite these positive forecasts, the stock displayed a bearish trend, suggesting potential disappointment or underperformance in the upcoming earnings release.
• The absence of the necessary factors for a likely earnings outperformance may have contributed to the prevailing bearish sentiment around BSX today.
• Comparisons with other medical sector stocks like Novavax (NVAX) and the relative strength ratings of companies such as Inari Medical (NARI) and ICU Medical (ICUI) could have diverted investor attention from Boston Scientific, resulting in a negative impact on its stock value.